PeptideInfo
العربيةGet the app
☰
Gastrointestinal researchResearch only

BPC-157 Stable

BPC-157 Stable Capsule

Not medical advice. Educational reference only.

Typical dose
100–250 mcg daily subcutaneously in research schedules
Route
Oral formulation; subcutaneous routes appear in the research protocol table
Storage
Keep refrigerated at 2–8 °C and use within 28 days.

What is BPC-157 Stable?

BPC-157 Stable is a stabilized oral version of BPC-157 intended for gastrointestinal research. It has no FDA approval and is barred from preparation by 503A compounding pharmacies.

Research indications

  • Tissue Repair

    Most effective

    Research investigates faster wound closure and repair of damaged soft tissue.

  • Gut Health

    Effective

    Potential gastrointestinal effects include support for intestinal lining integrity and digestive function.

  • Joint Support

    Effective

    Joint-related research examines lower inflammation together with better mobility.

  • Muscle Recovery

    Moderate

    Possible benefits include quicker recovery from muscle strains and stress associated with exercise.

Research protocols

These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.

GoalAmountFrequencyRoute
Starting Dose100 mcgOnce dailySubcutaneous injection
Standard Dose250 mcgOnce dailySubcutaneous injection

Interactions

  • TB-500 / BPC-157 (stack)

    Compatible

  • NSAIDs (Ibuprofen, Naproxen)

    Caution

  • Corticosteroids

    Caution

  • Anticoagulants

    Monitor

  • GH Secretagogues

    Compatible

  • NAD+

    Compatible

How to reconstitute and inject

Diluent: Use bacteriostatic water only; avoid saline because it may cause precipitation.

  1. Take the BPC-157 Stable vial out of the refrigerator and leave it for 15–20 minutes to reach room temperature.
  2. Disinfect the vial stopper with an alcohol swab. Wait until the alcohol has completely air-dried.
  3. Measure the calculated amount of bacteriostatic water into a sterile syringe. Use only bacteriostatic water; avoid saline because precipitation may occur.
  4. Add the water slowly along the inner wall of the vial. Keep the stream away from the powder itself.
  5. Rotate the vial gently to mix its contents. Never shake it vigorously, because this can degrade the peptide.
  6. Wait 2–3 minutes for the powder to dissolve completely. Check that the liquid is clear and has no color.
  7. Withdraw the calculated dose into an insulin syringe for administration beneath the skin.
  8. Inject into your abdomen, thigh or upper arm. Change the injection site each time to help prevent lipodystrophy.
  9. Refrigerate the mixed solution at 2–8 °C. Use it within 28 days after reconstitution.

What to expect

Week 1–2
Early anti-inflammatory effects may reduce pain and swelling around the affected tissue.
Week 2–4
Tissue mobility may improve as discomfort decreases and healing begins to progress more rapidly.
Week 4–8
Recovery may reach more substantial milestones, with better tissue repair and improved function.
Week 8–12
Later expectations include near-complete healing in many cases, increased strength and better tissue integrity. These intervals are research expectations, not established individual outcomes.

Side effects and safety

  • Mild nausea, especially with larger doses
  • Redness or soreness at the injection site
  • Lightheadedness or dizziness · Rare
  • Possible changes in blood pressure; monitor your pressure if you have hypertension

BPC-157 Stable: not approved in the US; 503A compounding banned.

Regulatory status

  • US

    Not approved

    FDA — research use only; no approval; 503A compounding is prohibited.

    Rx required
    No
    503A
    Banned
    Telehealth
    N/A

Frequently asked questions

What is BPC-157 Stable?

BPC-157 Stable is a stabilized oral version of BPC-157 intended for gastrointestinal research. It has no FDA approval and is barred from preparation by 503A compounding pharmacies.

What research applications are being explored for BPC-157 Stable?

Research examines tissue repair and gastrointestinal recovery. Findings for BPC-157 do not automatically establish results for this stabilized oral formulation.

Which doses appear in research discussions?

The starting research schedule uses 100 mcg by subcutaneous injection once daily; the standard schedule uses 250 mcg by the same route once daily. These are research figures, not an established human regimen. Discuss dosing and the intended indication with a licensed clinician. These subcutaneous schedules do not establish an oral dose or oral bioavailability.

What safety concerns need consideration?

Animal studies of healing peptides generally find good tolerability. Mild nausea, injection-site reactions and dizziness can occur, though rarely. Monitor your blood pressure if you have hypertension. Risk depends on dose, route and individual response.

References

  1. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (review) (2018)

  2. Stable gastric pentadecapeptide BPC 157: Novel therapy in gastrointestinal tract (2018)

  3. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing. (2021)

    PMID 34267654DOI 10.3389/fphar.2021.627533

  4. Fistulas Healing. Stable Gastric Pentadecapeptide BPC 157 Therapy. (2020)

    PMID 32329684DOI 10.2174/1381612826666200424180139